Diabetic retinopathy is a sight threatening disease without effective therapeutic options. The diabetic metabolic insult leading to retinal vascular degeneration is proposed to involve the initial endothelial cell damage due to low-grade chronic inflammation;that is then inadequately repaired due to compromised availability and functionality of bone marrow derived endothelial progenitor cells (EPCs). We have previously demonstrated that bone marrow pathology with EPC dysfunction precedes and is necessary for retinal vascular degeneration in diabetes. We propose that a molecular metabolic link connecting both the initial inflammation in the retina and the dysfunctional EPCs involves downregulation of ?-3 polyunsaturated fatty acids (PUFA) with concomitant activation of the central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Our recent study demonstrated a significant decrease in total 3-PUFAs, especially DHA, that was tightly coupled with increased inflammatory changes in the diabetic retina. DHA supplementation corrected the diabetes induced decrease in migration and proliferation in EPCs, and prevented diabetes induced retinal inflammation and retinal vessel loss. These findings fit with other studies showing potent anti-inflammatory properties of omega-3 PUFAs. Dysregulation of sphingolipid metabolism is believed to play a major role in insulin resistance, obesity and inflammation. We identified activation of ASM, the enzyme converting sphingomyelin into pro- inflammatory and pro-apoptotic ceramide, as a key element activated by diabetes in both EPCs and retinal vasculature. We found that DHA supplementation reversed increases in ASM activity in diabetic EPCs and retinal endothelial cells. ASM-/- animals were protected from vascular degeneration in retinopathy models. Based on these data we hypothesize that DHA supplementation improves the outcomes of diabetic retinopathy by: 1) preventing endothelial cell activation and subsequent damage in the retina;and 2) through improving retinal vascular repair by correcting the function of bone marrow derived EPCs. We propose that the beneficial effects of DHA are due, at least in part, to inhibition of ASM activity in retinal endothelial cells and bone marrow derived EPCs. This hypothesis will be tested in two Specific Aims.
Aim 1 will address retinal endothelial specific effects and Aim 2 will address EPC specific effects of ASM in diabetes. The proposed studies will assess the potential of ASM as a target for the treatment of diabetic retinopathy. Moreover, we will identify the extend of therapeutic potential that can be achieve by retinal-specific and bone-marrow specific inhibition of ASM to determine the best therapeutic strategies.

Public Health Relevance

Dysregulation of sphingolipid metabolism is becoming recognized as an important partof diabetic dyslipidemia playing a major role in insulin resistance; obesity andinflammation; and the role of sphingolipid metabolism in the retina is beginning toemerge. Our preliminary studies demonstrate that diets supplemented with 3 PUFA-rich effectively corrected retinal pathology in both type 1 and type 2 diabetes animalmodels through; at least in part; inhibition of acid sphingomyelinase; the major enzymeat the top of sphingolipid pathway. This proposal will address the role of acidsphingomyelinase activation in the pathogenesis of diabetic retinopathy and will providenovel therapeutic targets for this sight threatening disease.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY016077-07
Application #
8585067
Study Section
Biology and Diseases of the Posterior Eye Study Section (BDPE)
Program Officer
Shen, Grace L
Project Start
2004-12-01
Project End
2014-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
7
Fiscal Year
2014
Total Cost
$334,667
Indirect Cost
$95,947
Name
Michigan State University
Department
Physiology
Type
Schools of Osteopathic Medicine
DUNS #
193247145
City
East Lansing
State
MI
Country
United States
Zip Code
48824
Kady, Nermin M; Liu, Xuwen; Lydic, Todd A et al. (2018) ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. Diabetes 67:769-781
Huang, Chao; Fisher, Kiera P; Hammer, Sandra S et al. (2018) Plasma Exosomes Contribute to Microvascular Damage in Diabetic Retinopathy by Activating the Classical Complement Pathway. Diabetes 67:1639-1649
Baumler, Stephen M; McHale, Andrew M; Blanchard, G J (2018) Surface Charge and Overlayer pH Influence the Dynamics of Supported Phospholipid Films. J Electroanal Chem (Lausanne) 812:159-165
Malek, Goldis; Busik, Julia; Grant, Maria B et al. (2018) Models of retinal diseases and their applicability in drug discovery. Expert Opin Drug Discov 13:359-377
Kijewska, Krystyna; Blanchard, Gary J (2017) Using Diffusion To Characterize Interfacial Heterogeneity. Langmuir 33:1155-1161
Baumler, Stephen M; Blanchard, Gary J (2017) The Influence of Metal Ions on the Dynamics of Supported Phospholipid Langmuir Films. Langmuir 33:2986-2992
Kady, Nermin; Yan, Yuanqing; Salazar, Tatiana et al. (2017) Increase in acid sphingomyelinase level in human retinal endothelial cells and CD34+ circulating angiogenic cells isolated from diabetic individuals is associated with dysfunctional retinal vasculature and vascular repair process in diabetes. J Clin Lipidol 11:694-703
Bhatwadekar, Ashay D; Duan, Yaqian; Korah, Maria et al. (2017) Hematopoietic stem/progenitor involvement in retinal microvascular repair during diabetes: Implications for bone marrow rejuvenation. Vision Res 139:211-220
Hammer, Sandra S; Busik, Julia V (2017) The role of dyslipidemia in diabetic retinopathy. Vision Res 139:228-236
Blanchard, Gary J; Busik, Julia V (2017) Interplay between Endothelial Cell Cytoskeletal Rigidity and Plasma Membrane Fluidity. Biophys J 112:831-833

Showing the most recent 10 out of 35 publications